Focus: Trevi Therapeutics is a public biotech company focused on small-molecule therapeutics across respiratory, dermatology, and neurology indications. The company operates at clinical stage with a lean pipeline portfolio centered on nalbuphine ER formulations.
Profile data last refreshed 52m ago · AI intelligence enriched 3w ago
Early-stage biotech opportunity best suited for risk-tolerant professionals betting on nalbuphine ER success; limited hiring and cash constraints make this a speculative career move.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Trevi Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Trevi Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference - GlobeNewswire
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference GlobeNewswire
Patients reported early, sustained improvement in a chronic-cough trial - Stock Titan
Patients reported early, sustained improvement in a chronic-cough trial Stock Titan
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting - GlobeNewswire
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting GlobeNewswire
Trevi Therapeutics Inc Share Price - TRVI, RNS News, Articles, Quotes, & Charts (NASDAQ: TRVI) - Proactive financial news
Trevi Therapeutics Inc Share Price - TRVI, RNS News, Articles, Quotes, & Charts (NASDAQ: TRVI) Proactive financial news
Trevi Therapeutics Inc (TRVI-Q) Stock Price and News - The Globe and Mail
Trevi Therapeutics Inc (TRVI-Q) Stock Price and News The Globe and Mail
Trevi Therapeutics (TRVI) Following Its Pullback Still Carries An Undervalued Narrative - Simply Wall Street
Trevi Therapeutics (TRVI) Following Its Pullback Still Carries An Undervalued Narrative Simply Wall Street
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo